News and Trends 12 Dec 2019 Iterum Therapeutics Reels from Antibiotic Phase III Fail An antibiotic candidate developed by the Irish company Iterum Therapeutics has failed to meet the main goal of a phase III trial, a blow for efforts to meet the challenge of global antibiotic resistance. Iterum Therapeutics’ drug sulopenem was tested in a phase III trial that recruited 674 patients suffering from complicated intra-abdominal infections. These […] December 12, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Dec 2019 €14M Series A to Fund Cancer Immunotherapy Boosting Checkpoint Inhibitors The Swiss biotech ImmunOs Therapeutics has raised a Series A round of €13.7M (CHF 15M) that will fund the first human trials of its cancer immunotherapy that could improve the response of cancer patients to checkpoint inhibitors. The round was co-led by the Swiss life sciences venture capital firm BioMedPartners and by Pfizer Ventures. The […] December 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 11 Dec 2019 Collaboration Between Founders and Investors Primes Biotech Startups for Success How can entrepreneurs work with investors to maximize the chances of their company succeeding? Venture capital partner Nanna Lüneborg and biotech entrepreneur Mai-Britt Zocca spoke at Labiotech Refresh in Copenhagen about their experiences in founding IO Biotech, a Danish biotech startup that develops cancer immunotherapies. Zocca and Lüneborg were both involved in setting up IO […] December 11, 2019 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 10 Dec 2019 ObsEva’s Oral Treatment for Uterine Fibroids Nails Phase III An oral drug developed by the Swiss company ObsEva was shown to reduce menstrual bleeding and pain caused by uterine fibroids. The phase III trial tested ObsEva’s drug candidate linzagolix in 535 women suffering from heavy menstrual bleeding caused by benign tumors in the uterus called uterine fibroids. The effects of the drug were compared […] December 10, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2019 Scientists Use DNA Data Storage to Hide Information in Everyday Objects Scientists have developed a method for storing DNA data in 3D-printed objects, which could one day allow machines to replicate themselves. The group, based at ETH Zurich, Switzerland, as well as in Israel and the US, began by synthesizing DNA molecules that encode blueprints of the Stanford bunny, a rabbit-shaped object commonly used in testing […] December 9, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2019 Update: Cancer Immunotherapy Biotech Files for Insolvency Update (06/12/2019): Following the phase III failure of its immunotherapy drug for colorectal cancer in the summer, the German company Mologen has filed for insolvency. Published 06/08/2019 A DNA immunotherapy drug developed by the German company Mologen has failed to improve the survival of patients with colorectal cancer in a phase III trial. The phase […] December 6, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 5 Dec 2019 German Biotech Raises €7M Series A to Treat Acute Heart Failure 4TEEN4 Pharmaceuticals has raised a Series A round of €6.9M to fuel the development of a first-in-class antibody drug that could reduce mortality in acute heart failure. The round was led by Brandenburg Kapital, a subsidiary of the German investment bank Investitionsbank des Landes Brandenburg. Other investors in the round, including business angels and private […] December 5, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2019 €48M Series B Fuels Immunotherapies for Cancer and Autoimmune Diseases ImCheck Therapeutics has raised a Series B round worth €48M to fund the development of first-in-class immunotherapies that treat cancer and autoimmune diseases by targeting a rare type of immune cells called a gamma delta T-cell. ImCheck Therapeutics’ Series B round was led by Pfizer Ventures — the venture capital arm of the big pharma […] December 4, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 3 Dec 2019 Sensorion’s Vertigo Drug Abandoned in Phase II A small molecule drug developed by the French company Sensorion has proven ineffective in a phase IIb trial for the treatment of a rare vertigo condition, leading the company to close down the development of the drug. The phase IIb trial tested Sensorion’s lead drug in 105 patients with the rare condition acute unilateral vestibulopathy, […] December 3, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2019 €31M Series B Funds Rollout of Artificial Pancreas in Type 1 Diabetes The French biotech Diabeloop has raised €31M to launch an artificial pancreas device designed to automatically control the blood glucose levels of type 1 diabetes patients. According to Diabeloop, this is the biggest Series B round raised by a European company developing therapies that use artificial intelligence. The round was led by the French family […] December 2, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 29 Nov 2019 MedinCell Granted €17M to Develop Cheap Long-Acting Contraception The French company MedinCell has received a €17.3M ($19M) grant from the Bill and Melinda Gates Foundation to advance its long-acting contraceptive implant to human trials. The grant is a follow-on to a €3.2M endowment from the Gates Foundation in 2017 to fuel early preclinical development of the implant. The additional funds will help MedinCell […] November 29, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 28 Nov 2019 German Biotech to Develop Next-Generation Gene Therapy for Blindness The German biotech ViGeneron has raised an undisclosed sum in a Series A round to fund the development of an ophthalmic gene therapy that could deliver bigger DNA sequences into a wider range of cells than current technology. The round was led by two Chinese investors, the VC firm Sequoia Capital China and the pharma […] November 28, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email